Clinical reference Biomarker Directory
Back to directory

HBB

Established

HBB is the gene underlying sickle cell disease and beta-thalassemia, confirmed via genetic testing.

Also known as Beta-globin gene
In plain language

HBB is the gene for a key part of hemoglobin. Mutations in it cause sickle cell disease and thalassemia. Genetic testing of this gene helps confirm diagnoses and guide family planning decisions.

Biomarker & context

HBB encodes the beta-globin chain of hemoglobin; mutations in this gene cause sickle cell disease and beta-thalassemia, two of the most common inherited blood disorders worldwide.

What it indicates

HBB gene testing confirms sickle cell disease, sickle cell trait, and beta-thalassemia, complementing hemoglobin electrophoresis in diagnosis, especially for distinguishing carrier states from active disease and for prenatal/genetic counseling.

Diagnosis & clinical testing

Diagnosed via hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) as a first step, with HBB gene sequencing used for definitive genetic confirmation, carrier screening, and prenatal diagnosis.

Guiding treatment

Genetic confirmation informs family counseling and reproductive planning; it also underlies eligibility assessment for the newer gene therapies (see Hemoglobin S entry) now available for severe sickle cell disease.

Clinical significance

Complements hemoglobin electrophoresis for definitive diagnosis and genetic/reproductive counseling.

References
  1. General hematology/genetics reference literature on HBB-related hemoglobinopathies.